
Injective (INJ) recently experienced a price surge to $14.41, with increasing investor interest pointing towards even higher gains. Several factors are considered to be influencing this price growth including the rise in the number of Injective wallets which have breached the 4,000 mark. This has happened alongside the CBOE filing an ETF proposal for INJ, causing a buzz in the market.
Moreover, Injective has been trending after launching their EVM Testnet. This news precedes an analysis suggesting a targeted 60% price rally. Canary Capital has played a role by setting up a Delaware trust for a staked Injective ETF. This comes amidst news that Bithumb, a key cryptocurrency exchange, suspended INJ deposits and withdrawals in relation to an Injective network upgrade.
Importantly, INJ's compatibility test with EVM has drawn attention, predicting a rise of 130% for INJ crypto. Simultaneously, Deutsche Telekom is speculated to become a validator for the Injective blockchain, revealing a deeper strategic alliance. Furthermore, Injective has announced a joint program with Cointelegraph Accelerator for ecosystem acceleration, aimed at supporting blockchain startups.
Institutional recognition of the Injective Protocol is growing as well, as an INJ staked ETF gets filed for institutional adoption. Lastly, the Injective token has been tokenized for SharpLink's ETH Treasury, sparking a new wave in DeFi.
Injective Coin News Analytics from Thu, 03 Mar 2022 03:34:04 GMT to Wed, 20 Aug 2025 13:00:09 GMT - Rating 8 - Rumor 6